Results 211 to 220 of about 45,696 (262)

Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.

Lancet. Infectious Diseases (Print)
BACKGROUND Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce.
R. K. Shields, Lilian M. Abbo, Renee Ackley, Samuel L. Aitken, Benjamin Albrecht, Ahmed Babiker, R. Burgoon, Renzo Cifuentes, K. Claeys, Brooke N Curry, Kathryn DeSear, Jason C Gallagher, Esther Y. Golnabi, Alan E. Gross, Jonathan Hand, Emily L Heil, K. Hornback, Keith S Kaye, Trieu-Vi Khuu, Megan E Klatt, Ellen G. Kline, Ryan C. Kubat, W. Kufel, Jae Hyoung Lee, A. Lepak, Ahmi Lim, Justin Ludwig, C. MacDougall, Anjali Majumdar, Amy J Mathers, E. McCreary, William R Miller, M. Monogue, W. Moore, Shannon Olson, Jessica Oxer, J. Pearson, Christine Pham, Paulette Pinargote, C. Polk, M. Satlin, S. Satola, Sunish Shah, P. Tamma, T. Tran, D. van Duin, M. VanNatta, Ana Vega, V. Venugopalan, M. Veve, W. Wangchinda, Lucy S Witt, Janet Y. Wu, J. Pogue   +53 more
semanticscholar   +1 more source

Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study

Antimicrobial Agents and Chemotherapy, 2023
Ceftolozane-tazobactam (C-T) and ceftazidime-avibactam (CAZ-AVI) are two novel antimicrobials that retain activity against resistant Pseudomonas aeruginosa. The comparative effectiveness and safety of C-T versus CAZ-AVI remain unknown.
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Amin Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Y. Alsowaida   +14 more
semanticscholar   +1 more source

In Vitro Comparison of Aztreonam/Amoxicillin-Clavulanate Versus Aztreonam/Ceftazidime-Avibactam on Ceftazidime-Avibactam Resistant Stenotrophomonas maltophilia

Microbial Drug Resistance, 2022
We investigated the in vitro susceptibility of ceftazidime-avibactam (CZA) resistant Stenotrophomonas maltophilia to the associations aztreonam/amoxicillin-clavulanate (ATM-AMC) and ATM-CZA. Forty clinical isolates of S. maltophilia
Lise Crémet, Léo Joffraud, Emmanuel Eschapasse, Tiphaine Bihouée, Adrien Tissot, Sophie Gibaud, Elise Persyn   +6 more
openaire   +3 more sources

Ceftazidime/avibactam experience in tertiary hospital in Türkiye

Kastamonu Medical Journal, 2023
Aims: Real-life experience with ceftazidime/avibactam in the treatment of multidrug-resistant Klebsiella pneumoniae is still limited. This retrospective study aims to evaluate the efficacy of ceftazidime/avibactam in the treatment of critically ill patients with infections due to carbapenem-resistant pathogens.
Alper Tahmaz, Ayşegül Seremet Keskin
openaire   +1 more source

Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam

Antimicrobial Agents and Chemotherapy
Few studies compare outcomes of patients with difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.
Dariusz A. Hareza, Sara E. Cosgrove, R. Bonomo, Kathryn Dzintars, S. Karaba, A. Hawes, Tsigereda Tekle, P. Simner, P. Tamma   +8 more
semanticscholar   +1 more source

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes

International Journal of Antimicrobial Agents, 2014
For an antibacterial agent to be considered for clinical studies in nosocomial pneumonia (NP), it should be active in the presence of pulmonary surfactant. Furthermore, owing to the common practice of treating such infections with more than one antibacterial agent, it should be free of antagonistic interactions with agents of other classes.
John, Dallow, Linda G, Otterson, Michael D, Huband, Kevin M, Krause, Wright W, Nichols   +4 more
openaire   +2 more sources

Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to Stenotrophomonas maltophilia

Antimicrobial Agents and Chemotherapy
Clinical evidence is lacking regarding the efficacy of aztreonam-avibactam in severe infections involving Stenotrophomonas maltophilia. We report a case of post-neurosurgical meningitis due to S. maltophilia (minimal inhibitory concentration of aztreonam
Jonathan Wong-So, S. Magréault, Étienne Carbonnelle, Vincent Jullien, Maxime Desgrouas, Thierry Boulain, François Barbier   +6 more
semanticscholar   +1 more source

Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections

The Consultant Pharmacist, 2015
To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosing, and administration of ceftazidime/avibactam (CAZ/AVI).A search of PubMed using the terms "ceftazidime," "avibactam," "NXL104," and "AVE1330A" was performed. The manufacturer's website was also reviewed to further identify relevant
Elias B, Chahine, Mariette, Sourial, Raquel, Ortiz   +2 more
openaire   +2 more sources

In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study (2022-23).

Journal of Antimicrobial Chemotherapy
OBJECTIVES To evaluate the in vitro activity of ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae (KPC-Kp) clinical isolates collected from a multicentre study in Italy (2022-23)
G. Bianco, M. Boattini, L. Lupo, Simone Ambretti, Rita Greco, Linda Degl’Innocenti, Sofia Chiatamone Ranieri, T. Fasciana, A. Mazzariol, Davide Gibellini, Guido Antonelli, Federica Sacco, A. Quirino, C. Farina, Bianca Paglietti, S. Comini, M. Fiamma, Francesco Broccolo, R. Cavallo, Cristina Costa, P. Gaibani   +20 more
semanticscholar   +1 more source

Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections

Expert Opinion on Pharmacotherapy, 2016
The treatment of complicated intra-abdominal infections (cIAI) is increasingly challenging due to increased resistance of Gram-negative organisms. These multidrug resistant organisms lead to an increase in morbidity and mortality. This has led to renewed interest in use of older β-lactam antibiotics in combination with newer β-lactamase inhibitors ...
Sara A, Buckman, Tamara, Krekel, Anouk E, Muller, John E, Mazuski   +3 more
openaire   +2 more sources